Skip to Content
s - Skip to Content
0 - Access key details
1 - Back to top
2 - Header search

5 Slide Series

Volume 58

Hepatitis C Medication Market Share

The March 2018 edition of our 5 Slide Series tracks the national Medicaid market share and pre-rebate cost per prescription progression of curative Hepatitis C drugs from CY2014 through CY2017. The introduction of newer, lower cost-per-unit drugs has resulted in a significant shift in market share within this category of drugs. Additionally, we have quantified the considerable market share differences between MCO-paid and FFS-paid Medicaid prescriptions. 

Back to top